Mutated Citrullinated Vimentin (MCV) Antibody

There are no preparation instructions.

The following is a list of what is included in the item above. Click the test(s) below to view what biomarkers are measured along with an explanation of what the biomarker is measuring.


*Important Information on Lab Test Processing Times: Ulta Lab Tests is committed to informing you about the processing times for your lab tests processed through Quest Diagnostics. Please note that the estimated processing time for each test, indicated in business days, is based on data from the past 30 days across the 13 Quest Diagnostics laboratories for each test. These estimates are intended to serve as a guide and are not guarantees. Factors such as laboratory workload, weather conditions, holidays, and the need for additional testing or maintenance can influence actual processing times. We aim to offer estimates to help you plan accordingly. Please understand that these times may vary, and processing times are not guaranteed. Thank you for choosing Ulta Lab Tests for your laboratory needs.

The Mutated Citrullinated Vimentin (MCV) Antibody test contains 1 test with 1 biomarker.

Test Description for Mutated Citrullinated Vimentin (MCV) Antibody:

Name: Mutated Citrullinated Vimentin (MCV) Antibody Test

Also Known as: anti-MCV,RA,Rheumatoid arthritis

Purpose: The Mutated Citrullinated Vimentin (MCV) Antibody test is utilized as a secondary marker in the diagnosis of rheumatoid arthritis (RA). It serves to complement primary markers like rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibodies.

Test Significance: Anti-MCV antibodies are part of a group of anti-citrullinated protein antibodies (ACPAs) that target mutated citrullinated vimentin. While the MCV antibody test is slightly less specific than the anti-CCP test, it offers marginally higher sensitivity. Including an MCV antibody test alongside the CCP test can enhance the sensitivity of RA diagnosis by an additional 5-10%.

Clinical Relevance: The presence of MCV antibodies is not only indicative of RA but is also correlated with a more aggressive disease course. Patients who test positive for MCV antibodies often exhibit more severe RA symptoms and show greater radiological progression over time.

Testing Methodology: The detection of MCV antibodies is typically conducted via immunoassays that quantify the level of these antibodies in the patient's blood.

Interpretation: Positive results for MCV antibodies may necessitate further investigation and can be a significant factor in the management and treatment planning of rheumatoid arthritis, due to its association with more severe disease prognosis.

Reference Range(s)
<20 U/mL

Note: The test is most effective when used in conjunction with other RA markers, and results should be evaluated by a healthcare professional within the broader context of clinical findings and patient history.

Customer Reviews